- Home
- CYH vs ERAS Comparison
CYH vs ERAS Comparison
Compare CYH & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- ERAS
- Stock Information
- Founded
- CYH 1985
- ERAS 2018
- Country
- CYH United States
- ERAS United States
- Employees
- CYH N/A
- ERAS N/A
- Industry
- CYH Hospital/Nursing Management
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- ERAS Health Care
- Exchange
- CYH Nasdaq
- ERAS Nasdaq
- Market Cap
- CYH 623.8M
- ERAS 719.0M
- IPO Year
- CYH 1991
- ERAS 2021
- Fundamental
- Price
- CYH $3.74
- ERAS $2.60
- Analyst Decision
- CYH Hold
- ERAS Strong Buy
- Analyst Count
- CYH 5
- ERAS 6
- Target Price
- CYH $5.20
- ERAS $6.08
- AVG Volume (30 Days)
- CYH 2.0M
- ERAS 1.7M
- Earning Date
- CYH 10-23-2024
- ERAS 11-12-2024
- Dividend Yield
- CYH N/A
- ERAS N/A
- EPS Growth
- CYH N/A
- ERAS N/A
- EPS
- CYH N/A
- ERAS N/A
- Revenue
- CYH $12,551,000,000.00
- ERAS N/A
- Revenue This Year
- CYH $1.19
- ERAS N/A
- Revenue Next Year
- CYH $1.48
- ERAS N/A
- P/E Ratio
- CYH N/A
- ERAS N/A
- Revenue Growth
- CYH 0.81
- ERAS N/A
- 52 Week Low
- CYH $2.31
- ERAS $1.51
- 52 Week High
- CYH $6.29
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CYH 31.56
- ERAS 41.83
- Support Level
- CYH $3.61
- ERAS $2.62
- Resistance Level
- CYH $3.85
- ERAS $2.97
- Average True Range (ATR)
- CYH 0.24
- ERAS 0.21
- MACD
- CYH -0.02
- ERAS -0.04
- Stochastic Oscillator
- CYH 20.61
- ERAS 11.32
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.